MXPA06007574A - Inmunogenos dirigidos. - Google Patents

Inmunogenos dirigidos.

Info

Publication number
MXPA06007574A
MXPA06007574A MXPA06007574A MXPA06007574A MXPA06007574A MX PA06007574 A MXPA06007574 A MX PA06007574A MX PA06007574 A MXPA06007574 A MX PA06007574A MX PA06007574 A MXPA06007574 A MX PA06007574A MX PA06007574 A MXPA06007574 A MX PA06007574A
Authority
MX
Mexico
Prior art keywords
sequence
amino acid
seq
peptide
hperl
Prior art date
Application number
MXPA06007574A
Other languages
English (en)
Spanish (es)
Inventor
Scott Gallichan
Robert A Uger
Danielle Salha
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of MXPA06007574A publication Critical patent/MXPA06007574A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA06007574A 2003-12-31 2004-12-30 Inmunogenos dirigidos. MXPA06007574A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53372803P 2003-12-31 2003-12-31
PCT/US2004/044023 WO2005066203A2 (en) 2003-12-31 2004-12-30 Targeted immunogens

Publications (1)

Publication Number Publication Date
MXPA06007574A true MXPA06007574A (es) 2007-04-17

Family

ID=34748948

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06007574A MXPA06007574A (es) 2003-12-31 2004-12-30 Inmunogenos dirigidos.

Country Status (12)

Country Link
US (1) US20060002946A1 (enExample)
EP (1) EP1699492A2 (enExample)
JP (1) JP2007536911A (enExample)
KR (1) KR20060129353A (enExample)
CN (1) CN1921889A (enExample)
AU (1) AU2004312548A1 (enExample)
BR (1) BRPI0418273A (enExample)
CA (1) CA2552251A1 (enExample)
IL (1) IL176603A0 (enExample)
MX (1) MXPA06007574A (enExample)
WO (1) WO2005066203A2 (enExample)
ZA (1) ZA200605304B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103110D0 (en) * 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
KR20170116039A (ko) * 2015-02-18 2017-10-18 에프. 호프만-라 로슈 아게 표적 세포에 대항하여 t 세포 세포독성을 특이적으로 유도하기 위한 면역컨주게이트
CA2984629C (en) 2015-05-07 2024-06-18 University Of South Florida Modified ube3a gene for a gene therapy approach for angelman syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE391791T1 (de) * 2000-08-25 2008-04-15 Aventis Pharma Inc Membran penetrierende peptide und deren anwendungen
CA2477429A1 (en) * 2002-01-29 2003-08-07 Robert A. Uger Targeted immunogens

Also Published As

Publication number Publication date
WO2005066203A2 (en) 2005-07-21
IL176603A0 (en) 2006-10-31
US20060002946A1 (en) 2006-01-05
CN1921889A (zh) 2007-02-28
WO2005066203A3 (en) 2005-09-01
JP2007536911A (ja) 2007-12-20
BRPI0418273A (pt) 2007-05-02
EP1699492A2 (en) 2006-09-13
KR20060129353A (ko) 2006-12-15
AU2004312548A1 (en) 2005-07-21
CA2552251A1 (en) 2005-07-21
ZA200605304B (en) 2007-12-27

Similar Documents

Publication Publication Date Title
AU2011200127B2 (en) Multi-antigen vectors for melanoma
US20110311543A1 (en) Tumor Antigens BFA5 for Prevention and/or Treatment of Cancer
US8530442B2 (en) Modified CEA nucleic acid and expression vectors
EP1864691B1 (en) Modified CEA nucleic acid and expression vectors
US20030113919A1 (en) Immunogenic targets for melanoma
US20040002455A1 (en) Targeted immunogens
US20030148973A1 (en) MAGE-A1 peptides for treating or preventing cancer
US20060002946A1 (en) Targeted immunogens
AU2004280608B2 (en) Modified CEA/B7 vector
AU2003216119A1 (en) Targeted immunogens
CN1878566B (zh) 用于黑素瘤的多抗原载体
US20090156519A1 (en) Modified KSA and Uses Thereof
US20050158332A1 (en) MHC-Class II restricted melanoma antigens and their use in therapeutic methods
MXPA06002477A (en) Multi-antigen vectors for melanoma
MXPA06003911A (en) Modified cea /b7 vector
HK1102553A (en) Targeted immunogens
HK1101352B (en) Multi-antigen vectors for melanoma